Journal Article
. 2018 Nov; 120(1):115-127.
doi: 10.1038/s41416-018-0313-5.

VISTA expressed in tumour cells regulates T cell function

Kumuluzi Mulati 1 Junzo Hamanishi 2 Noriomi Matsumura 3 Kenji Chamoto 4 Nathan Mise 5 Kaoru Abiko 1 Tsukasa Baba 1 Ken Yamaguchi 6 Naoki Horikawa 1 Ryusuke Murakami 1 Mana Taki 1 Kharma Budiman 1 Xiang Zeng 1 Yuko Hosoe 1 Miyuki Azuma 7 Ikuo Konishi 6 Masaki Mandai 1 
  • PMID: 30382166
  •     46 References
  •     47 citations


Background: V-domain Ig suppressor of T cell activation (VISTA) is a novel inhibitory immune-checkpoint protein. VISTA expression on tumour cells and the associated regulatory mechanisms remain unclear. We investigated VISTA expression and function in tumour cells, and evaluated its mechanism and activity.

Methods: VISTA in tumour cells was assessed by tissue microarray analysis, immunohistochemical staining and western blot. A series of in vitro assays were used to determine the function of tumour-expressed VISTA. In vivo efficacy was evaluated in syngeneic models.

Results: VISTA was highly expressed in human ovarian and endometrial cancers. Upregulation of VISTA in endometrial cancer was related to the methylation status of the VISTA promoter. VISTA in tumour cells suppressed T cell proliferation and cytokine production in vitro, and decreased the tumour-infiltrating CD8+ T cells in vivo. Anti-VISTA antibody prolonged the survival of tumour-bearing mice.

Conclusions: This is the first demonstration that VISTA is highly expressed in human ovarian and endometrial cancer cells, and that anti-VISTA antibody treatment significantly prolongs the survival of mice bearing tumours expressing high levels of VISTA. The data suggest that VISTA is a novel immunosuppressive factor within the tumour microenvironment, as well as a new target for cancer immunotherapy.

PD-1 and its ligands in tolerance and immunity.
Mary E Keir, Manish J Butte, Gordon J Freeman, Arlene H Sharpe.
Annu Rev Immunol, 2008 Jan 05; 26. PMID: 18173375
Highly Cited. Review.
Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer.
Franz Villarroel-Espindola, Xiaoqing Yu, +9 authors, Kurt A Schalper.
Clin Cancer Res, 2017 Dec 06; 24(7). PMID: 29203588    Free PMC article.
Cancer statistics, 2009.
Ahmedin Jemal, Rebecca Siegel, +3 authors, Michael J Thun.
CA Cancer J Clin, 2009 May 29; 59(4). PMID: 19474385
Highly Cited.
The management of recurrent ovarian cancer.
Ronald M Bukowski, Robert F Ozols, Maurie Markman.
Semin Oncol, 2007 May 22; 34(2 Suppl 2). PMID: 17512352
VISTA is an immune checkpoint molecule for human T cells.
J Louise Lines, Eirini Pantazi, +8 authors, Randolph Noelle.
Cancer Res, 2014 Apr 03; 74(7). PMID: 24691993    Free PMC article.
Highly Cited.
Activated local immunity by CC chemokine ligand 19-transduced embryonic endothelial progenitor cells suppresses metastasis of murine ovarian cancer.
Junzo Hamanishi, Masaki Mandai, +4 authors, Ikuo Konishi.
Stem Cells, 2009 Nov 17; 28(1). PMID: 19911426
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Hossein Borghaei, Luis Paz-Ares, +25 authors, Julie R Brahmer.
N Engl J Med, 2015 Sep 29; 373(17). PMID: 26412456    Free PMC article.
Highly Cited.
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer.
Jianjun Gao, John F Ward, +16 authors, Padmanee Sharma.
Nat Med, 2017 Mar 28; 23(5). PMID: 28346412    Free PMC article.
Highly Cited.
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer.
Junzo Hamanishi, Masaki Mandai, +9 authors, Shingo Fujii.
Proc Natl Acad Sci U S A, 2007 Mar 16; 104(9). PMID: 17360651    Free PMC article.
Highly Cited.
Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study.
Patrick A Ott, Yung-Jue Bang, +11 authors, Jean-Charles Soria.
J Clin Oncol, 2017 May 11; 35(22). PMID: 28489510
Highly Cited.
Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.
Junzo Hamanishi, Masaki Mandai, +18 authors, Ikuo Konishi.
J Clin Oncol, 2015 Sep 10; 33(34). PMID: 26351349
Highly Cited.
VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy.
J Louise Lines, Lorenzo F Sempere, +2 authors, Randolph Noelle.
Cancer Immunol Res, 2014 Jun 05; 2(6). PMID: 24894088    Free PMC article.
Highly Cited.
Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors.
Francesca De Felice, Claudia Marchetti, +4 authors, Pierluigi Benedetti Panici.
J Immunol Res, 2015 Aug 04; 2015. PMID: 26236750    Free PMC article.
Immune Checkpoint Molecule, VISTA Regulates T-Cell-Mediated Skin Inflammatory Responses.
Tatsukuni Ohno, Yuta Kondo, +2 authors, Miyuki Azuma.
J Invest Dermatol, 2017 Jan 21; 137(6). PMID: 28104378
miR-125b regulates the early steps of ESC differentiation through dies1 in a TGF-independent manner.
Marica Battista, Anna Musto, +3 authors, Silvia Parisi.
Int J Mol Sci, 2013 Jun 29; 14(7). PMID: 23807506    Free PMC article.
Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma.
Yuta Kondo, Tatsukuni Ohno, +3 authors, Miyuki Azuma.
Oral Oncol, 2016 May 22; 57. PMID: 27208845
Ovarian cancer in 2015: Insights into strategies for optimizing ovarian cancer care.
Robert L Coleman.
Nat Rev Clin Oncol, 2016 Jan 01; 13(2). PMID: 26718108
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.
Jacques Ferlay, Isabelle Soerjomataram, +6 authors, Freddie Bray.
Int J Cancer, 2014 Sep 16; 136(5). PMID: 25220842
Highly Cited.
Development of a syngeneic mouse model for events related to ovarian cancer.
K F Roby, C C Taylor, +6 authors, P F Terranova.
Carcinogenesis, 2000 Apr 07; 21(4). PMID: 10753190
Highly Cited.
Immune Checkpoint Blockade in Cancer Therapy.
Michael A Postow, Margaret K Callahan, Jedd D Wolchok.
J Clin Oncol, 2015 Jan 22; 33(17). PMID: 25605845    Free PMC article.
Highly Cited. Review.
Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity.
Li Wang, Isabelle Le Mercier, +7 authors, Randolph J Noelle.
Proc Natl Acad Sci U S A, 2014 Oct 01; 111(41). PMID: 25267631    Free PMC article.
Immunotherapy for ovarian cancer: what's next?
Lana E Kandalaft, Daniel J Powell, Nathan Singh, George Coukos.
J Clin Oncol, 2010 Nov 17; 29(7). PMID: 21079136    Free PMC article.
Mechanistic Assessment of PD-1H Coinhibitory Receptor-Induced T Cell Tolerance to Allogeneic Antigens.
Dallas B Flies, Tomoe Higuchi, Lieping Chen.
J Immunol, 2015 Apr 29; 194(11). PMID: 25917101    Free PMC article.
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L Topalian, F Stephen Hodi, +27 authors, Mario Sznol.
N Engl J Med, 2012 Jun 05; 366(26). PMID: 22658127    Free PMC article.
Highly Cited.
Nivolumab in previously untreated melanoma without BRAF mutation.
Caroline Robert, Georgina V Long, +25 authors, Paolo A Ascierto.
N Engl J Med, 2014 Nov 18; 372(4). PMID: 25399552
Highly Cited.
Myeloid-derived suppressor cells as regulators of the immune system.
Dmitry I Gabrilovich, Srinivas Nagaraj.
Nat Rev Immunol, 2009 Feb 07; 9(3). PMID: 19197294    Free PMC article.
Highly Cited. Review.
VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses.
Li Wang, Rotem Rubinstein, +10 authors, Randolph J Noelle.
J Exp Med, 2011 Mar 09; 208(3). PMID: 21383057    Free PMC article.
Highly Cited.
Membranous and Cytoplasmic Expression of PD-L1 in Ovarian Cancer Cells.
Qiu-Xia Qu, Fang Xie, Qin Huang, Xue-Guang Zhang.
Cell Physiol Biochem, 2017 Oct 23; 43(5). PMID: 29055949
Inhibitory B7-family molecules in the tumour microenvironment.
Weiping Zou, Lieping Chen.
Nat Rev Immunol, 2008 May 27; 8(6). PMID: 18500231
Highly Cited. Review.
Scoring of PD-L1 expression intensity on pulmonary adenocarcinomas and the correlations with clinicopathological factors.
Tomoyuki Igarashi, Koji Teramoto, +2 authors, Yataro Daigo.
ESMO Open, 2016 Nov 16; 1(4). PMID: 27843633    Free PMC article.
DNA methylation and epigenetic inheritance.
Robin Holliday, Thu Ho.
Methods, 2002 Jul 04; 27(2). PMID: 12095278
Control of signaling-mediated clearance of apoptotic cells by the tumor suppressor p53.
Kyoung Wan Yoon, Sanguine Byun, +13 authors, Sam W Lee.
Science, 2015 Aug 01; 349(6247). PMID: 26228159    Free PMC article.
Highly Cited.
GI24 enhances tumor invasiveness by regulating cell surface membrane-type 1 matrix metalloproteinase.
Moustafa A Sakr, Takahisa Takino, +5 authors, Hiroshi Sato.
Cancer Sci, 2010 Jul 30; 101(11). PMID: 20666777
A regulatory loop involving Dies1 and miR-125a controls BMP4 signaling in mouse embryonic stem cells.
Silvia Parisi, Marica Battista, +3 authors, Tommaso Russo.
FASEB J, 2012 Jul 04; 26(10). PMID: 22751012
PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells.
Kathleen M Mahoney, Heather Sun, +8 authors, Gordon J Freeman.
Cancer Immunol Res, 2015 Nov 08; 3(12). PMID: 26546452    Free PMC article.
Highly Cited.
Targeting Programmed Cell Death 1 in Ovarian Cancer.
Krisztian Homicsko, George Coukos.
J Clin Oncol, 2015 Oct 28; 33(34). PMID: 26503205
Coinhibitory receptor PD-1H preferentially suppresses CD4⁺ T cell-mediated immunity.
Dallas B Flies, Xue Han, +4 authors, Lieping Chen.
J Clin Invest, 2014 Apr 20; 124(5). PMID: 24743150    Free PMC article.
Highly Cited.
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer.
Mario Sznol, Lieping Chen.
Clin Cancer Res, 2013 Mar 06; 19(5). PMID: 23460533    Free PMC article.
Highly Cited.
VISTA Regulates the Development of Protective Antitumor Immunity.
Isabelle Le Mercier, Wenna Chen, +5 authors, Li Wang.
Cancer Res, 2014 Apr 03; 74(7). PMID: 24691994    Free PMC article.
Highly Cited.
Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.
Jianjiong Gao, Bülent Arman Aksoy, +10 authors, Nikolaus Schultz.
Sci Signal, 2013 Apr 04; 6(269). PMID: 23550210    Free PMC article.
Highly Cited.
Pembrolizumab versus Ipilimumab in Advanced Melanoma.
Caroline Robert, Jacob Schachter, +20 authors, KEYNOTE-006 investigators.
N Engl J Med, 2015 Apr 22; 372(26). PMID: 25891173
Highly Cited.
Dies1/VISTA expression loss is a recurrent event in gastric cancer due to epigenetic regulation.
Patrícia Oliveira, Joana Carvalho, +9 authors, Carla Oliveira.
Sci Rep, 2016 Oct 11; 6. PMID: 27721458    Free PMC article.
Integrated genomic characterization of endometrial carcinoma.
Cancer Genome Atlas Research Network, Cyriac Kandoth, +16 authors, Douglas A Levine.
Nature, 2013 May 03; 497(7447). PMID: 23636398    Free PMC article.
Highly Cited.
Identifier mapping performance for integrating transcriptomics and proteomics experimental results.
Roger S Day, Kevin K McDade, +7 authors, G Larry Maxwell.
BMC Bioinformatics, 2011 May 31; 12. PMID: 21619611    Free PMC article.
Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses.
Jun Liu, Ying Yuan, +8 authors, Li Wang.
Proc Natl Acad Sci U S A, 2015 May 13; 112(21). PMID: 25964334    Free PMC article.
Highly Cited.
Coordinated regulation of myeloid cells by tumours.
Dmitry I Gabrilovich, Suzanne Ostrand-Rosenberg, Vincenzo Bronte.
Nat Rev Immunol, 2012 Mar 23; 12(4). PMID: 22437938    Free PMC article.
Highly Cited. Review.
Targeting Negative and Positive Immune Checkpoints with Monoclonal Antibodies in Therapy of Cancer.
Katsiaryna Marhelava, Zofia Pilch, +2 authors, Radoslaw Zagozdzon.
Cancers (Basel), 2019 Nov 14; 11(11). PMID: 31717326    Free PMC article.
The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy.
Gerard J Chu, Nico van Zandwijk, John E J Rasko.
Front Oncol, 2019 Dec 24; 9. PMID: 31867277    Free PMC article.
VISTA expression is associated with a favorable prognosis in patients with high-grade serous ovarian cancer.
Liju Zong, Yuncan Zhou, +2 authors, Yang Xiang.
Cancer Immunol Immunother, 2019 Nov 30; 69(1). PMID: 31781843    Free PMC article.
FOXD3 Regulates VISTA Expression in Melanoma.
Sheera R Rosenbaum, Meghan Knecht, +11 authors, Andrew E Aplin.
Cell Rep, 2020 Jan 16; 30(2). PMID: 31940493    Free PMC article.
Reverting Immune Suppression to Enhance Cancer Immunotherapy.
Bella S Guerrouahen, Cristina Maccalli, +2 authors, Emmanuel T Akporiaye.
Front Oncol, 2020 Feb 11; 9. PMID: 32039024    Free PMC article.
VISTA: Coming of age as a multi-lineage immune checkpoint.
M A ElTanbouly, E Schaafsma, R J Noelle, J L Lines.
Clin Exp Immunol, 2020 Jan 14; 200(2). PMID: 31930484    Free PMC article.
VISTA: a novel immunotherapy target for normalizing innate and adaptive immunity.
Mohamed A ElTanbouly, Walburga Croteau, Randolph J Noelle, J Louise Lines.
Semin Immunol, 2019 Oct 13; 42. PMID: 31604531    Free PMC article.
Novel Immunotherapy Combinations.
Babar Bashir, Melissa A Wilson.
Curr Oncol Rep, 2019 Nov 07; 21(11). PMID: 31696332
VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy.
Xing Huang, Xiaozhen Zhang, +5 authors, Tingbo Liang.
J Hematol Oncol, 2020 Jul 01; 13(1). PMID: 32600443    Free PMC article.
Immunotherapies and Combination Strategies for Immuno-Oncology.
Cody Barbari, Tyler Fontaine, +4 authors, Rahul R Deshmukh.
Int J Mol Sci, 2020 Jul 19; 21(14). PMID: 32679922    Free PMC article.
Immune disorder in endometrial cancer: Immunosuppressive microenvironment, mechanisms of immune evasion and immunotherapy.
Lei Zhan, Xiaojing Liu, +2 authors, Bing Wei.
Oncol Lett, 2020 Aug 13; 20(3). PMID: 32782525    Free PMC article.
Expression and clinical significance of PD-L1, B7-H3, B7-H4 and VISTA in craniopharyngioma.
Yuelong Wang, Jiaojiao Deng, +10 authors, Jianguo Xu.
J Immunother Cancer, 2020 Sep 23; 8(2). PMID: 32958683    Free PMC article.
Exploring the VISTA of microglia: immune checkpoints in CNS inflammation.
Malte Borggrewe, Susanne M Kooistra, +2 authors, Jon D Laman.
J Mol Med (Berl), 2020 Aug 29; 98(10). PMID: 32856125    Free PMC article.
Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant.
Chang Yang, Bai-Rong Xia, +3 authors, Wei-Lin Jin.
Front Immunol, 2020 Oct 31; 11. PMID: 33123161    Free PMC article.
Alternative Checkpoints as Targets for Immunotherapy.
Ayush Pant, Ravi Medikonda, Michael Lim.
Curr Oncol Rep, 2020 Nov 04; 22(12). PMID: 33141349    Free PMC article.
Emerging Targets of Immunotherapy in Gynecologic Cancer.
Hongyan Cheng, Liju Zong, +3 authors, Yang Xiang.
Onco Targets Ther, 2020 Nov 27; 13. PMID: 33239889    Free PMC article.
Prognostic significance and therapeutic potential of the immune checkpoint VISTA in pancreatic cancer.
Zelin Hou, Yu Pan, +8 authors, Heguang Huang.
J Cancer Res Clin Oncol, 2020 Nov 26; 147(2). PMID: 33237432    Free PMC article.
Expression of VISTA on tumor-infiltrating immune cells correlated with short intravesical recurrence in non-muscle-invasive bladder cancer.
Won Ik Seo, Chan Ho Lee, +6 authors, Inhak Choi.
Cancer Immunol Immunother, 2021 Mar 27; 70(11). PMID: 33770210
Chemotherapy regimens induce inhibitory immune checkpoint protein expression on stem-like and senescent-like oesophageal adenocarcinoma cells.
Maria Davern, Noel E Donlon, +10 authors, Joanne Lysaght.
Transl Oncol, 2021 Mar 26; 14(6). PMID: 33765543    Free PMC article.
VISTA: A Mediator of Quiescence and a Promising Target in Cancer Immunotherapy.
Long Yuan, Jahnavi Tatineni, Kathleen M Mahoney, Gordon J Freeman.
Trends Immunol, 2021 Jan 27; 42(3). PMID: 33495077    Free PMC article.
Terminating Cancer by Blocking VISTA as a Novel Immunotherapy: Hasta la vista, baby.
Ji-Eun Irene Yum, Young-Kwon Hong.
Front Oncol, 2021 May 04; 11. PMID: 33937071    Free PMC article.
Endometrial Cancer Suppresses CD8+ T Cell-Mediated Cytotoxicity in Postmenopausal Women.
Mickey V Patel, Zheng Shen, +3 authors, Charles R Wira.
Front Immunol, 2021 May 11; 12. PMID: 33968059    Free PMC article.
Tumor-infiltrating CD8+ T cell antitumor efficacy and exhaustion: molecular insights.
Sandeep Kumar, Sunil Kumar Singh, Basabi Rana, Ajay Rana.
Drug Discov Today, 2021 Jan 16; 26(4). PMID: 33450394    Free PMC article.
Characterization of Immune Cell Subsets of Tumor Infiltrating Lymphocytes in Brain Metastases.
Priyakshi Kalita-de Croft, Haarika Chittoory, +11 authors, Sunil R Lakhani.
Biology (Basel), 2021 Jun 03; 10(5). PMID: 34064871    Free PMC article.
The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead.
Negar Hosseinkhani, Afshin Derakhshani, +7 authors, Behzad Baradaran.
Front Immunol, 2021 Jun 08; 12. PMID: 34093577    Free PMC article.
Mechanism-based treatment of cancer with immune checkpoint inhibitor therapies.
Yara Abdou, Manu Pandey, +3 authors, Marc S Ernstoff.
Br J Clin Pharmacol, 2020 Apr 24; 86(9). PMID: 32323342    Free PMC article.
Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapy.
Martin Thelen, Kerstin Wennhold, +22 authors, Hans A Schlößer.
NPJ Precis Oncol, 2021 Jun 18; 5(1). PMID: 34135436    Free PMC article.
Nano-immunotherapy for each stage of cancer cellular immunity: which, why, and what?
Shiyi Zuo, Jiaxuan Song, +3 authors, Jin Sun.
Theranostics, 2021 Jun 24; 11(15). PMID: 34158861    Free PMC article.
VISTA: A Promising Target for Cancer Immunotherapy?
Marco Tagliamento, Elisa Agostinetto, +4 authors, Matteo Lambertini.
Immunotargets Ther, 2021 Jul 01; 10. PMID: 34189130    Free PMC article.
Ovarian Cancer: Therapeutic Strategies to Overcome Immune Suppression.
Maureen L Drakes, Patrick J Stiff.
Adv Exp Med Biol, 2021 Aug 03; 1330. PMID: 34339029
The Role of Mathematical Models in Immuno-Oncology: Challenges and Future Perspectives.
Aymara Sancho-Araiz, Victor Mangas-Sanjuan, Iñaki F Trocóniz.
Pharmaceutics, 2021 Aug 11; 13(7). PMID: 34371708    Free PMC article.
Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy.
Juwon Lee, Youngjin Han, +7 authors, Yong Sang Song.
Biomolecules, 2021 Aug 28; 11(8). PMID: 34439774    Free PMC article.
The immune checkpoint VISTA exhibits high expression levels in human gliomas and associates with a poor prognosis.
Amina Ghouzlani, Abdelhakim Lakhdar, +2 authors, Abdallah Badou.
Sci Rep, 2021 Nov 04; 11(1). PMID: 34728682    Free PMC article.
Discovery of Novel Inhibitors From Medicinal Plants for V-Domain Ig Suppressor of T-Cell Activation.
Iqra Muneer, Sajjad Ahmad, +8 authors, Muhammad Tahir Ul Qamar.
Front Mol Biosci, 2021 Nov 13; 8. PMID: 34765641    Free PMC article.
VISTA inhibitors in cancer immunotherapy: a short perspective on recent progresses.
Chenyang Wu, Xin Cao, Xiaojin Zhang.
RSC Med Chem, 2021 Nov 16; 12(10). PMID: 34778768    Free PMC article.
VISTA Is a Diagnostic Biomarker and Immunotherapy Target of Aggressive Feline Mammary Carcinoma Subtypes.
Andreia Gameiro, Catarina Nascimento, Jorge Correia, Fernando Ferreira.
Cancers (Basel), 2021 Nov 14; 13(21). PMID: 34771722    Free PMC article.
Type 1 Innate Lymphoid Cells Limit the Antitumoral Immune Response.
Margaux Vienne, Marion Etiennot, +6 authors, Yann M Kerdiles.
Front Immunol, 2021 Dec 07; 12. PMID: 34868026    Free PMC article.
Old and New Players of Inflammation and Their Relationship With Cancer Development.
Rodolfo Chavez-Dominguez, Mario Perez-Medina, +5 authors, Jose S Lopez-Gonzalez.
Front Oncol, 2021 Dec 10; 11. PMID: 34881173    Free PMC article.
PD-1H Expression Associated With CD68 Macrophage Marker Confers an Immune-Activated Microenvironment and Favorable Overall Survival in Human Esophageal Squamous Cell Carcinoma.
Yuangui Chen, Rui Feng, +4 authors, Qiuyu Zhang.
Front Mol Biosci, 2021 Dec 25; 8. PMID: 34950702    Free PMC article.
Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions.
Katrin Pansy, Barbara Uhl, +9 authors, Alexander Ja Deutsch.
Int J Mol Sci, 2021 Dec 25; 22(24). PMID: 34948104    Free PMC article.
Upregulated Fibulin-1 Increased Endometrial Stromal Cell Viability and Migration by Repressing EFEMP1-Dependent Ferroptosis in Endometriosis.
Yiting Wan, Yanhua Song, +4 authors, Ling Zuo.
Biomed Res Int, 2022 Feb 08; 2022. PMID: 35127942    Free PMC article.
Rationally targeted anti-VISTA antibody that blockades the C-C' loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner.
Dipti Thakkar, Shalini Paliwal, +9 authors, Jerome D Boyd-Kirkup.
J Immunother Cancer, 2022 Feb 09; 10(2). PMID: 35131861    Free PMC article.
VISTA in Soft Tissue Sarcomas: A Perspective for Immunotherapy?
Markus Albertsmeier, Annelore Altendorf-Hofmann, +8 authors, Thomas Knösel.
Cancers (Basel), 2022 Feb 26; 14(4). PMID: 35205752    Free PMC article.
PD-1 and TIGIT blockade differentially affect tumour cell survival under hypoxia and glucose deprived conditions in oesophageal adenocarcinoma; implications for overcoming resistance to PD-1 blockade in hypoxic tumours.
Maria Davern, Marie-Claire Fitzgerald, +13 authors, Joanne Lysaght.
Transl Oncol, 2022 Mar 05; 19. PMID: 35245832    Free PMC article.
Evolution of Molecular Targeted Cancer Therapy: Mechanisms of Drug Resistance and Novel Opportunities Identified by CRISPR-Cas9 Screening.
Jue Hou, Zongsheng He, +4 authors, Xi Zheng.
Front Oncol, 2022 Apr 05; 12. PMID: 35372044    Free PMC article.
ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation.
Zheqi Li, Olivia McGinn, +23 authors, Steffi Oesterreich.
Nat Commun, 2022 Apr 21; 13(1). PMID: 35440136    Free PMC article.
Identify the Prognostic and Immune Profile of VSIR in the Tumor Microenvironment: A Pan-Cancer Analysis.
Yuanyuan Liu, Jingwei Zhang, +12 authors, Quan Cheng.
Front Cell Dev Biol, 2022 May 03; 10. PMID: 35493077    Free PMC article.